Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden.


Journal

Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614

Informations de publication

Date de publication:
31 10 2021
Historique:
pubmed: 9 9 2021
medline: 27 1 2022
entrez: 8 9 2021
Statut: ppublish

Résumé

There is a critical need for improved pharmacodynamic markers for use in human tuberculosis (TB) drug trials. Pharmacodynamic monitoring in TB has conventionally used culture or molecular methods to enumerate the burden of Mycobacterium tuberculosis organisms in sputum. A recently proposed assay called the rRNA synthesis (RS) ratio measures a fundamentally novel property, how drugs impact ongoing bacterial rRNA synthesis. Here, we evaluated RS ratio as a potential pharmacodynamic monitoring tool by testing pretreatment sputa from 38 Ugandan adults with drug-susceptible pulmonary TB. We quantified the RS ratio in paired pretreatment sputa and evaluated the relationship between the RS ratio and microbiologic and molecular markers of M. tuberculosis burden. We found that the RS ratio was highly repeatable and reproducible in sputum samples. The RS ratio was independent of M. tuberculosis burden, confirming that it measures a distinct new property. In contrast, markers of M. tuberculosis burden were strongly associated with each other. These results indicate that the RS ratio is repeatable and reproducible and provides a distinct type of information from markers of M. tuberculosis burden.

Identifiants

pubmed: 34494858
doi: 10.1128/Spectrum.00481-21
pmc: PMC8557932
doi:

Substances chimiques

Biomarkers 0
RNA, Bacterial 0
RNA, Ribosomal 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0048121

Subventions

Organisme : FIC NIH HHS
ID : D43 TW009607
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128156
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL098964
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI135652
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL087713
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127300
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL090335
Pays : United States
Organisme : BLRD VA
ID : I01 BX004527
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL143998
Pays : United States
Organisme : CSRD VA
ID : IK2 CX000914
Pays : United States

Références

Adv Drug Deliv Rev. 2016 Jul 1;102:116-22
pubmed: 26827911
Lancet. 2015 May 2;385(9979):1799-1801
pubmed: 25814376
Am J Respir Crit Care Med. 2011 Oct 15;184(8):972-9
pubmed: 21737585
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Am J Respir Crit Care Med. 2009 Sep 15;180(6):558-63
pubmed: 19542476
BMC Med. 2016 Feb 23;14:36
pubmed: 26905218
Afr Health Sci. 2018 Sep;18(3):512-522
pubmed: 30602982
BMC Infect Dis. 2012 Aug 01;12:172
pubmed: 22853561
PLoS One. 2010 Mar 26;5(3):e9859
pubmed: 20361038
PLoS One. 2017 Aug 10;12(8):e0182872
pubmed: 28796824
Lancet Infect Dis. 2010 Jun;10(6):387-94
pubmed: 20510279
Nat Rev Neurol. 2020 Jul;16(7):381-400
pubmed: 32541893
Nat Commun. 2021 May 18;12(1):2899
pubmed: 34006838
PLoS One. 2013 May 02;8(5):e62583
pubmed: 23658750
Circulation. 2011 Mar 15;123(10):1116-24
pubmed: 21403122
Respir Physiol Neurobiol. 2018 Aug;254:36-39
pubmed: 29684501
Clin Transl Sci. 2017 Sep;10(5):366-379
pubmed: 28561946
Jpn J Infect Dis. 2007 May;60(2-3):73-5
pubmed: 17515635
Stat Med. 1994 Dec 15-30;13(23-24):2465-76
pubmed: 7701147
J Clin Microbiol. 2014 Aug;52(8):3064-7
pubmed: 24871215
PLoS One. 2019 May 15;14(5):e0216680
pubmed: 31091258
Clin Chim Acta. 2016 Dec 1;463:129-137
pubmed: 27756543
PLoS One. 2013 May 08;8(5):e63840
pubmed: 23667677
Appl Environ Microbiol. 2014 Oct;80(19):5884-91
pubmed: 25038100
J Clin Microbiol. 2015 Apr;53(4):1087-91
pubmed: 25552362
Trans R Soc Trop Med Hyg. 2014 Jan;108(1):55-6
pubmed: 24277790
J Clin Microbiol. 2011 Nov;49(11):3905-11
pubmed: 21900522

Auteurs

Emmanuel Musisi (E)

Infectious Disease Research Collaboration, Kampala, Uganda.
Department of Biochemistry, Makerere University, Kampala, Uganda.
Department of Medical and Biological Sciences, Infection and Global Health Division, University of St. Andrews, St. Andrews, United Kingdom.

Christian Dide-Agossou (C)

Department of Epidemiology, Colorado School of Public Healthgrid.414594.9, Aurora, Colorado, USA.

Reem Al Mubarak (R)

Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA.
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Karen Rossmassler (K)

Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA.
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

Abdul Wahab Ssesolo (AW)

Infectious Disease Research Collaboration, Kampala, Uganda.

Sylvia Kaswabuli (S)

Infectious Disease Research Collaboration, Kampala, Uganda.

Patrick Byanyima (P)

Infectious Disease Research Collaboration, Kampala, Uganda.

Ingvar Sanyu (I)

Infectious Disease Research Collaboration, Kampala, Uganda.

Josephine Zawedde (J)

Infectious Disease Research Collaboration, Kampala, Uganda.

William Worodria (W)

Infectious Disease Research Collaboration, Kampala, Uganda.

Martin I Voskuil (MI)

Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Consortium for Applied Microbial Metrics, Aurora, Colorado, USA.

Rada M Savic (RM)

Consortium for Applied Microbial Metrics, Aurora, Colorado, USA.
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.

Payam Nahid (P)

Consortium for Applied Microbial Metrics, Aurora, Colorado, USA.
Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
UCSF Center for Tuberculosis, San Francisco, California, USA.

J Lucian Davis (JL)

Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Pulmonary, Critical Care, and Sleep Medicine Section, Yale School of Medicine, New Haven, Connecticut, USA.

Laurence Huang (L)

Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Zuckerberg San Francisco General Hospital, San Francisco, California, USA.

Camille M Moore (CM)

Division of Biostatistics and Bioinformatics, National Jewish Health, Denver, Colorado, USA.

Nicholas D Walter (ND)

Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA.
Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Consortium for Applied Microbial Metrics, Aurora, Colorado, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH